Becton Dickinson and Co (NYSE:BDX) Shares Acquired by Meeder Asset Management Inc.

Share on StockTwits

Meeder Asset Management Inc. lifted its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 2,353.8% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 319 shares of the medical instruments supplier’s stock after buying an additional 306 shares during the period. Meeder Asset Management Inc.’s holdings in Becton Dickinson and were worth $80,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in BDX. Thoroughbred Financial Services LLC boosted its stake in shares of Becton Dickinson and by 25,302.2% during the second quarter. Thoroughbred Financial Services LLC now owns 990,940 shares of the medical instruments supplier’s stock worth $99,094,000 after buying an additional 987,039 shares during the period. FMR LLC boosted its stake in shares of Becton Dickinson and by 5.0% during the first quarter. FMR LLC now owns 17,835,000 shares of the medical instruments supplier’s stock worth $4,453,934,000 after buying an additional 842,590 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Becton Dickinson and by 10.4% during the first quarter. JPMorgan Chase & Co. now owns 4,418,870 shares of the medical instruments supplier’s stock worth $1,103,526,000 after buying an additional 416,459 shares during the period. Intermede Investment Partners Ltd acquired a new stake in shares of Becton Dickinson and during the second quarter worth about $76,019,000. Finally, California Public Employees Retirement System boosted its stake in shares of Becton Dickinson and by 29.9% during the first quarter. California Public Employees Retirement System now owns 971,355 shares of the medical instruments supplier’s stock worth $242,576,000 after buying an additional 223,484 shares during the period. Institutional investors and hedge funds own 82.82% of the company’s stock.

Shares of Becton Dickinson and stock opened at $249.83 on Wednesday. Becton Dickinson and Co has a 12-month low of $208.62 and a 12-month high of $265.87. The company has a current ratio of 1.09, a quick ratio of 0.67 and a debt-to-equity ratio of 0.84. The stock has a market cap of $67.03 billion, a PE ratio of 22.69, a price-to-earnings-growth ratio of 1.80 and a beta of 1.11. The company has a 50-day moving average of $251.22 and a two-hundred day moving average of $244.55.

Becton Dickinson and (NYSE:BDX) last issued its earnings results on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.05 by $0.03. Becton Dickinson and had a net margin of 5.02% and a return on equity of 14.78%. The company had revenue of $4.35 billion during the quarter, compared to analysts’ expectations of $4.37 billion. During the same period last year, the company posted $2.91 earnings per share. The firm’s quarterly revenue was up 1.7% compared to the same quarter last year. On average, sell-side analysts forecast that Becton Dickinson and Co will post 11.68 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be issued a $0.77 dividend. The ex-dividend date of this dividend is Friday, September 6th. This represents a $3.08 dividend on an annualized basis and a yield of 1.23%. Becton Dickinson and’s dividend payout ratio (DPR) is presently 27.97%.

In other news, EVP Patrick Kaltenbach sold 275 shares of the firm’s stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $235.00, for a total transaction of $64,625.00. Following the completion of the transaction, the executive vice president now directly owns 16,482 shares of the company’s stock, valued at approximately $3,873,270. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Roland Goette sold 1,717 shares of the firm’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $249.88, for a total transaction of $429,043.96. Following the transaction, the executive vice president now directly owns 19,966 shares of the company’s stock, valued at $4,989,104.08. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 8,444 shares of company stock valued at $2,061,288. 0.12% of the stock is currently owned by corporate insiders.

Several equities research analysts have recently weighed in on the stock. ValuEngine downgraded shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Wells Fargo & Co reduced their price objective on shares of Becton Dickinson and from $280.00 to $265.00 and set an “outperform” rating for the company in a research report on Monday, May 13th. UBS Group reduced their price objective on shares of Becton Dickinson and from $265.00 to $250.00 and set a “neutral” rating for the company in a research report on Friday, May 10th. BMO Capital Markets reduced their price objective on shares of Becton Dickinson and from $272.00 to $270.00 and set a “market perform” rating for the company in a research report on Friday, May 10th. Finally, Morgan Stanley raised their price objective on shares of Becton Dickinson and from $250.00 to $261.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 16th. Five analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $264.27.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Story: How can investors benefit from after-hours trading?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Jefferies Financial Group Analysts Cut Earnings Estimates for Lexington Realty Trust
Jefferies Financial Group Analysts Cut Earnings Estimates for Lexington Realty Trust
FY2019 EPS Estimates for Jacobs Engineering Group Inc  Lifted by Analyst
FY2019 EPS Estimates for Jacobs Engineering Group Inc Lifted by Analyst
FY2019 EPS Estimates for Manulife Financial Co. Boosted by Analyst
FY2019 EPS Estimates for Manulife Financial Co. Boosted by Analyst
Reata Pharmaceuticals Inc to Post FY2019 Earnings of  Per Share, Cantor Fitzgerald Forecasts
Reata Pharmaceuticals Inc to Post FY2019 Earnings of Per Share, Cantor Fitzgerald Forecasts
CGI Inc  Holdings Decreased by Financial Gravity Wealth Inc.
CGI Inc Holdings Decreased by Financial Gravity Wealth Inc.
Brokers Offer Predictions for Astronics Co.’s Q3 2019 Earnings
Brokers Offer Predictions for Astronics Co.’s Q3 2019 Earnings


© 2006-2019 Ticker Report